ClinicalTrials.gg
Active, not recruitingNCT04075292Updated Sep 14, 2026Results posted

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

A Phase 3 interventional study of Acalabrutinib and Rituximab in Untreated Chronic Lymphocytic Leukemia, sponsored by AstraZeneca. Active, not recruiting at 46 sites in 5 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
11th of 39
155 · median 61
Started
2020
with 5 others
Phase 3
9 of 39
1 open now
Primary completion
2024-01
later than 7 of 27 live
Registered
16th of 39
by date
Lead sponsor
7 of 39
AstraZeneca

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 11th largest by enrollment, is one of 6 that started in 2020, is one of 9 in phase 3, reaches primary completion later than 7 of the 27 other live ones, and was the 16th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

Read the detailed description

Patients be randomized in a 1:1 ratio into 2 arms to receive either acalabrutinib monotherapy (Arm A) or rituximab in combination with chlorambucil (Arm B). The primary objective of this study is to compare the efficacy of acalabrutinib relative to chlorambucil plus rituximab in subjects with previously untreated chronic lymphocytic leukemia without del(17p) or TP53 mutation.

03

Conditions studied

  • Untreated Chronic Lymphocytic Leukemia

Keywords

  • Chronic Lymphocytic Leukemia
  • Acalabrutinib
  • Progression-free Survival
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women: (a) ≥65 years of age OR (b) >18 and \<65 years of age, provided that they meet at least one of the following criteria: (i) 30 to 69 mL/min using the Cockcroft-Gault equation (iwCLL guidelines) (ii) A score higher than 6 on the Cumulative Illness Rating Score-Geriatric (CIRS G)
  • performance status of 0, 1, or 2
  • Diagnosis of CLL that meets published diagnostic criteria (Hallek 2018)
  • Active disease per IWCLL 2018 criteria that requires treatment
  • Adequate bone marrow function
  • Adequate renal and hepatic function

Exclusion criteria

Exclusion Criteria:

  • Known detected del(17p) or TP53 mutation
  • Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (eg, Richter's transformation, PLL, or diffuse large B cell lymphoma [DLBCL]), or central nervous system (CNS) involvement by leukemia
  • History of prior except for the following: (a) Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study (b) Other cancers not specified above which have been curatively treated by surgery and/or radiation therapy from which subject is disease-free for ≥3 years without further treatment
  • Significant cardiovascular disease
  • Known history of infection with (HIV)
  • Serologic status reflecting active or C infection
  • Any active systemic infection (eg, bacterial, viral, or fungal infection) requiring systemic treatment
  • History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
  • Major surgical procedure within 30 days of first dose of study drug
  • Any prior CLL-specific therapies
  • use >20 mg within 1 week before first dose of study drug, except as indicated for other medical conditions
  • Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists
  • For women only: breastfeeding or pregnant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Acalabrutinib

    Acalabrutinib will be orally administered until disease progression or unacceptable toxicity

    Drug: Acalabrutinib

  • Active comparator
    Rituximab and Chlorambucil

    Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles

    Drug: Rituximab · Drug: Chlorambucil

Interventions

  • acalabrutinib 100 mg twice daily orally

  • Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)

  • Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Assessed by BICR

    PFS was defined as the time from randomization to PD (assessed by BICR according to International Workshop on Chronic Lymphocytic Leukaemia \[iwCLL\] 2018 guideline criteria) or death due to any cause. PD was defined as meeting at least 1 of the below criteria of groups(g) A or B. gA: increase of ≥50% from baseline (BL) or from response in lymph nodes or liver and/or spleen size; any constitutional symptoms; increase of ≥50% over nadir with absolute count ≥ 5×10\^9/liter (L) in circulating lymphocyte count (CLC); gB: decrease of ≥50% from BL secondary to CLL in platelet count; decrease of ≥2 gram per deciliter (g/dL) from BL secondary to CLL in hemoglobin (Hb); increase of CLL cells by ≥50% on successive biopsies in bone marrow (BM). Median PFS was calculated using Kaplan-Meier method and its confidence interval (CI) using Brookmeyer-Crowley method.

    Time frame: Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD or death, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)

Secondary outcomes

  1. Overall Response Rate (ORR) Assessed by BICR and Investigator

    ORR:percentage of participants with complete response(CR),CR with incomplete BM recovery(CRi), partial response(PR)/nodular PR(nPR) assessed by BICR;investigator per IWCLL 2018 criteria at/before initiation of subsequent anti-cancer therapy.CR:No lymph nodes(target lesions)≥1.5 centimeter(cm), spleen\<13cm,normal liver;CLC,no constitutional symptoms,platelets≥100,000/microliter(μL),Hb≥11.0 g/dL,BM:normocellular,no CLL cells\&B-lymphoid nodules.PR:atleast 2 gA parameters;1 gB parameter need to improve if previously abnormal.If only 1 parameter of both gA,B was abnormal prior to therapy,only 1 needs to improve.gA:Decrease≥50% from BL in lymph nodes,liver \& or spleen size,CLC;any constitutional symptoms, gB:platelet≥100,000/μL or increase 50% over BL;Hb≥11g/dL or increase≥50% over BL;BM:presence of CLL cells/B-lymphoid nodules/not done.CRi:all CR criteria+persistent anemia,thrombocytopenia or neutropenia unrelated to CLL,related to drug toxicity.nPR:CR+presence of B-lymphoid nodules in BM.

    Time frame: Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD or death, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)

  2. Duration of Response (DOR) Assessed by BICR and Investigator

    DOR was defined as the time from response (date of first documented response) to PD or death (absence of PD) as judged by BICR and investigator. PD was defined as meeting at least 1 of the below criteria of group A or group B. Group A: Increase of ≥ 50% from BL or from response in lymph nodes or liver and/or spleen size; any constitutional symptoms; increase of ≥50% over nadir with absolute count ≥ 5×10\^9/L in CLC; group B: decrease of ≥50% from BL secondary to CLL in platelet count; decrease of ≥2 g/dL from BL secondary to CLL in hemoglobin; increase of CLL cells by ≥50% on successive biopsies in marrow. Median DOR was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

    Time frame: Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD or death, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)

  3. Time to Next Treatment (TTNT)

    TTNT was defined as the time from the date of randomization to the date of initiation of non-protocol-specified anti-CLL therapy (either medication or radiotherapy for CLL) or death from any cause, whichever occurred first. Median TTNT was calculated using Kaplan-Meier method and its CI was calculated using Brookmeyer-Crowley method.

    Time frame: Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD, and survival follow-ups performed every 12 weeks thereafter, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)

  4. Overall Survival (OS)

    OS was defined as the time from the date of randomization until death due to any cause. The median OS was calculated using Kaplan-Meier method and its CI was calculated using Brookmeyer-Crowley method.

    Time frame: From date of randomization until death due to any cause, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)

  5. Minimal Residual Disease (MRD) Negativity Rate

    The MRD negative rate was defined as the percentage of participants with MRD-negativity (defined as \<1 CLL cell per 10,000 leukocytes) measured in the peripheral blood by flow cytometry.

    Time frame: At Cycle 9 (cycle duration: 28 days)

  6. Plasma Concentrations of Acalabrutinib and Its Metabolite ACP-5862

    Blood samples were collected to determine the concentration of acalabrutinib and its metabolite ACP-5862 in plasma.

    Time frame: Pre-dose, and at 1, 2, 4 hours post-dose on Day 1 of Cycle 2 (cycle duration: 28 days)

Other outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence (other than progression of the malignancy under evaluation) in participant or clinical study participant administered medicinal product and which does not necessarily had a causal relationship with treatment. A serious adverse event (SAE) was an AE occurring during any study phase, that fulfilled 1 or more of following criteria: resulted in death, was life-threatening, required in-participant hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was congenital abnormality or birth defect, and was an important medical event that jeopardized participant or required medical treatment to prevent 1 of outcomes listed above. TEAE was any AE that occurred or worsened in severity on or after date of the first dose of study drug up to 30 days after last dose of study drug or prior to initiation of a new anti-CLL therapy, whichever occurred first.

    Time frame: From first dose of study drug (Day 1) up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)

07

Results

Posted Jan 30, 2025

Participant flow

This Phase III, multicenter, randomized, open-label study was conducted in participants with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation at 46 sites across 5 countries. Results are presented up to data cut-off (DCO) date of 03 January 2024.

Participant flow — Overall Study
MilestoneAcalabrutinibChlorambucil Plus Rituximab
Started7778
Safety analysis set (sas)7773
Completed00
Not completed7778
Withdrew: Withdrawal by subject19
Withdrew: Death25
Withdrew: Remained on study at time of dco7464

Outcome measures

PrimaryProgression Free Survival (PFS) Assessed by BICR

PFS was defined as the time from randomization to PD (assessed by BICR according to International Workshop on Chronic Lymphocytic Leukaemia \[iwCLL\] 2018 guideline criteria) or death due to any cause. PD was defined as meeting at least 1 of the below criteria of groups(g) A or B. gA: increase of ≥50% from baseline (BL) or from response in lymph nodes or liver and/or spleen size; any constitutional symptoms; increase of ≥50% over nadir with absolute count ≥ 5×10\^9/liter (L) in circulating lymphocyte count (CLC); gB: decrease of ≥50% from BL secondary to CLL in platelet count; decrease of ≥2 gram per deciliter (g/dL) from BL secondary to CLL in hemoglobin (Hb); increase of CLL cells by ≥50% on successive biopsies in bone marrow (BM). Median PFS was calculated using Kaplan-Meier method and its confidence interval (CI) using Brookmeyer-Crowley method.

Time frame:
Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD or death, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)
Reported as:
Median · months
Progression Free Survival (PFS) Assessed by BICR
monthsAcalabrutinibChlorambucil Plus Rituximab
Progression Free Survival (PFS) Assessed by BICRNA (NA to NA)15.54 (11.53 to 17.54)
Statistical analysis
  • Acalabrutinib vs Chlorambucil Plus Rituximab · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.08 · 95% CI 0.03 to 0.18HR was calculated using an unstratified Cox model with treatment as the only covariate. The CI for HR was calculated using the profile likelihood method.
SecondaryOverall Response Rate (ORR) Assessed by BICR and Investigator

ORR:percentage of participants with complete response(CR),CR with incomplete BM recovery(CRi), partial response(PR)/nodular PR(nPR) assessed by BICR;investigator per IWCLL 2018 criteria at/before initiation of subsequent anti-cancer therapy.CR:No lymph nodes(target lesions)≥1.5 centimeter(cm), spleen\<13cm,normal liver;CLC,no constitutional symptoms,platelets≥100,000/microliter(μL),Hb≥11.0 g/dL,BM:normocellular,no CLL cells\&B-lymphoid nodules.PR:atleast 2 gA parameters;1 gB parameter need to improve if previously abnormal.If only 1 parameter of both gA,B was abnormal prior to therapy,only 1 needs to improve.gA:Decrease≥50% from BL in lymph nodes,liver \& or spleen size,CLC;any constitutional symptoms, gB:platelet≥100,000/μL or increase 50% over BL;Hb≥11g/dL or increase≥50% over BL;BM:presence of CLL cells/B-lymphoid nodules/not done.CRi:all CR criteria+persistent anemia,thrombocytopenia or neutropenia unrelated to CLL,related to drug toxicity.nPR:CR+presence of B-lymphoid nodules in BM.

Time frame:
Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD or death, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Assessed by BICR and Investigator
percentage of participantsAcalabrutinibChlorambucil Plus Rituximab
BICR Assessment76.671.8
Investigator Assessment81.860.3
SecondaryDuration of Response (DOR) Assessed by BICR and Investigator

DOR was defined as the time from response (date of first documented response) to PD or death (absence of PD) as judged by BICR and investigator. PD was defined as meeting at least 1 of the below criteria of group A or group B. Group A: Increase of ≥ 50% from BL or from response in lymph nodes or liver and/or spleen size; any constitutional symptoms; increase of ≥50% over nadir with absolute count ≥ 5×10\^9/L in CLC; group B: decrease of ≥50% from BL secondary to CLL in platelet count; decrease of ≥2 g/dL from BL secondary to CLL in hemoglobin; increase of CLL cells by ≥50% on successive biopsies in marrow. Median DOR was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

Time frame:
Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD or death, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)
Reported as:
Median · months
Duration of Response (DOR) Assessed by BICR and Investigator
monthsAcalabrutinibChlorambucil Plus Rituximab
BICR AssessmentNA (NA to NA)11.56 (8.28 to 14.26)
Investigator AssessmentNA (30.55 to NA)19.29 (11.47 to NA)
SecondaryTime to Next Treatment (TTNT)

TTNT was defined as the time from the date of randomization to the date of initiation of non-protocol-specified anti-CLL therapy (either medication or radiotherapy for CLL) or death from any cause, whichever occurred first. Median TTNT was calculated using Kaplan-Meier method and its CI was calculated using Brookmeyer-Crowley method.

Time frame:
Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD, and survival follow-ups performed every 12 weeks thereafter, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)
Reported as:
Median · months
Time to Next Treatment (TTNT)
monthsAcalabrutinibChlorambucil Plus Rituximab
Time to Next Treatment (TTNT)NA (NA to NA)26.22 (19.48 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization until death due to any cause. The median OS was calculated using Kaplan-Meier method and its CI was calculated using Brookmeyer-Crowley method.

Time frame:
From date of randomization until death due to any cause, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)
Reported as:
Median · months
Overall Survival (OS)
monthsAcalabrutinibChlorambucil Plus Rituximab
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryMinimal Residual Disease (MRD) Negativity Rate

The MRD negative rate was defined as the percentage of participants with MRD-negativity (defined as \<1 CLL cell per 10,000 leukocytes) measured in the peripheral blood by flow cytometry.

Time frame:
At Cycle 9 (cycle duration: 28 days)
Reported as:
Number · percentage of participants
Minimal Residual Disease (MRD) Negativity Rate
percentage of participantsAcalabrutinibChlorambucil Plus Rituximab
Minimal Residual Disease (MRD) Negativity Rate1.311.5
SecondaryPlasma Concentrations of Acalabrutinib and Its Metabolite ACP-5862

Blood samples were collected to determine the concentration of acalabrutinib and its metabolite ACP-5862 in plasma.

Time frame:
Pre-dose, and at 1, 2, 4 hours post-dose on Day 1 of Cycle 2 (cycle duration: 28 days)
Reported as:
Geometric mean · nanogram per milliliter
Plasma Concentrations of Acalabrutinib and Its Metabolite ACP-5862
nanogram per milliliterAcalabrutinib
Acalabrutinib: Pre-dose4.057 ± 123.8
Acalabrutinib: 1 hour post-dose131.941 ± 424.5
Acalabrutinib: 2 hours post-dose176.728 ± 131.9
Acalabrutinib: 4 hours post-dose56.822 ± 112.0
ACP-5862: Pre-dose52.314 ± 60.4
ACP-5862: 1 hour post-dose183.15 ± 176.1
ACP-5862: 2 hours post-dose298.758 ± 102.1
ACP-5862: 4 hours post-dose222.881 ± 72.0
Other pre-specifiedNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence (other than progression of the malignancy under evaluation) in participant or clinical study participant administered medicinal product and which does not necessarily had a causal relationship with treatment. A serious adverse event (SAE) was an AE occurring during any study phase, that fulfilled 1 or more of following criteria: resulted in death, was life-threatening, required in-participant hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was congenital abnormality or birth defect, and was an important medical event that jeopardized participant or required medical treatment to prevent 1 of outcomes listed above. TEAE was any AE that occurred or worsened in severity on or after date of the first dose of study drug up to 30 days after last dose of study drug or prior to initiation of a new anti-CLL therapy, whichever occurred first.

Time frame:
From first dose of study drug (Day 1) up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsAcalabrutinibChlorambucil Plus Rituximab
TEAEs7468
TESAEs3017

Adverse events

Collected over From first dose of study drug (Day 1) up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acalabrutinib2/77 (2.6%)30/77 (39%)67/77 (87%)
Chlorambucil Plus Rituximab5/78 (6.4%)17/73 (23.3%)61/73 (83.6%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventAcalabrutinibChlorambucil Plus Rituximab
PneumoniaInfections and infestations7/774/73
COVID-19Infections and infestations6/770/73
COVID-19 pneumoniaInfections and infestations5/771/73
Febrile neutropeniaBlood and lymphatic system disorders1/773/73
AnaemiaBlood and lymphatic system disorders3/772/73
Neutrophil count decreasedInvestigations0/772/73
Platelet count decreasedInvestigations1/772/73
Tumour lysis syndromeMetabolism and nutrition disorders0/772/73
NeutropeniaBlood and lymphatic system disorders2/771/73
ThrombocytopeniaBlood and lymphatic system disorders2/770/73
Most frequent other events
Showing 10 of 33
Most frequent other events
EventAcalabrutinibChlorambucil Plus Rituximab
COVID-19Infections and infestations22/7710/73
Neutrophil count decreasedInvestigations10/7718/73
HeadacheNervous system disorders15/776/73
DiarrhoeaGastrointestinal disorders12/772/73
NeutropeniaBlood and lymphatic system disorders2/7711/73
AnaemiaBlood and lymphatic system disorders9/7711/73
Lymphocyte count increasedInvestigations11/770/73
LeukocytosisBlood and lymphatic system disorders11/771/73
Platelet count decreasedInvestigations10/779/73
Weight increasedInvestigations10/776/73

Baseline characteristics

Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)AcalabrutinibChlorambucil Plus RituximabTotal
Median64.0 (38 to 86)67.0 (21 to 87)65.0 (21 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)AcalabrutinibChlorambucil Plus RituximabTotal
Female343165
Male434790
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AcalabrutinibChlorambucil Plus RituximabTotal
Asian7775152
White033
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AcalabrutinibChlorambucil Plus RituximabTotal
Hispanic or Latino022
Non-Hispanic or Latino7776153
08

Study locations

46 sites
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Changzhou, 272100, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Guiyang, 550004, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Qingdao, 110016, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Shanghai, 200050, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shijiazhuang, 050020, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Taiyuan, 030001, China
  • Research Site
    Tianjin, 300020, China
  • Research Site
    Xuzhou, 221000, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhengzhou, 450052, China
  • Research Site
    Baguio City, 2600, Philippines
  • Research Site
    Cebu, 6000, Philippines
  • Research Site
    Davao City, 8000, Philippines
  • Research Site
    Makati, 1229, Philippines
  • Research Site
    Manila, 1000, Philippines
  • Research Site
    Quezon City, 1112, Philippines
  • Research Site
    Chiayi City, 613, Taiwan
  • Research Site
    Hualien City, 97002, Taiwan
  • Research Site
    Kaohsiung City, 833, Taiwan
  • Research Site
    Taichung, 404, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Tainan, 704, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Bangkok, 10330, Thailand
  • Research Site
    Bangkok, 10400, Thailand
  • Research Site
    Bangkok, 10700, Thailand
  • Research Site
    Chiang Mai, 50200, Thailand
  • Research Site
    Hat Yai, 90110, Thailand
  • Research Site
    Khon Kaen, 40002, Thailand
  • Research Site
    Hanoi, 100000, Vietnam
  • Research Site
    Ho Chi Minh City, 700000, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Jan 2024, 47 months.

Results were first posted in Jan 2025, 1 year after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 47 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2019
First posted
Aug 30, 2019
StartActual
Jan 20, 2020
Primary completionActual
Jan 3, 2024
CompletionEst.
Jan 1, 2027
Results first posted
Jan 30, 2025
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04075292
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 30, 2019
Start date
Jan 20, 2020
Primary completion
Jan 3, 2024
Completion
Jan 1, 2027 (estimated)
Results posted
Jan 30, 2025
Last update
Sep 14, 2026

Study contacts

Lugui Qiu, MD
principal investigator · Chinese Academy of Medical Science Affiliated Hospital of Hematology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion